![Minimax and admissible adaptive two-stage designs in phase II clinical trials | BMC Medical Research Methodology | Full Text Minimax and admissible adaptive two-stage designs in phase II clinical trials | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-016-0194-3/MediaObjects/12874_2016_194_Fig3_HTML.gif)
Minimax and admissible adaptive two-stage designs in phase II clinical trials | BMC Medical Research Methodology | Full Text
![Two-stage optimal designs with survival endpoint when the follow-up time is restricted | BMC Medical Research Methodology | Full Text Two-stage optimal designs with survival endpoint when the follow-up time is restricted | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-019-0696-x/MediaObjects/12874_2019_696_Fig2_HTML.png)
Two-stage optimal designs with survival endpoint when the follow-up time is restricted | BMC Medical Research Methodology | Full Text
![Optimal, minimax and admissible two-stage design for phase II oncology clinical trials | BMC Medical Research Methodology | Full Text Optimal, minimax and admissible two-stage design for phase II oncology clinical trials | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-020-01017-8/MediaObjects/12874_2020_1017_Fig2_HTML.png)
Optimal, minimax and admissible two-stage design for phase II oncology clinical trials | BMC Medical Research Methodology | Full Text
![Optimal, minimax and admissible two-stage design for phase II oncology clinical trials | BMC Medical Research Methodology | Full Text Optimal, minimax and admissible two-stage design for phase II oncology clinical trials | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-020-01017-8/MediaObjects/12874_2020_1017_Fig4_HTML.png)
Optimal, minimax and admissible two-stage design for phase II oncology clinical trials | BMC Medical Research Methodology | Full Text
![Optimal, minimax and admissible two-stage design for phase II oncology clinical trials | BMC Medical Research Methodology | Full Text Optimal, minimax and admissible two-stage design for phase II oncology clinical trials | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-020-01017-8/MediaObjects/12874_2020_1017_Fig3_HTML.png)
Optimal, minimax and admissible two-stage design for phase II oncology clinical trials | BMC Medical Research Methodology | Full Text
![A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials. | Semantic Scholar A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a6e62b16707086a034f7512cf8cfb86ac684a0ab/5-Table3-1.png)
A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials. | Semantic Scholar
Optimal two-stage design of single arm Phase II clinical trials based on median event time test | PLOS ONE
![A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials. | Semantic Scholar A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a6e62b16707086a034f7512cf8cfb86ac684a0ab/4-Table1-1.png)